|
|||||
|
|
Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: A multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer |
|
| Institution: | 1. Department of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands;2. Department of Radiation Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands;3. Division of Surgery, Department of Clinical Science, Intervention and Technology, Karolinska Institute, Stockholm, Sweden;4. Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden;5. Department of Medical Oncology, University Cancer Center Leipzig, Leipzig University Medical Center, Leipzig, Germany;6. Department of Oncology, Cambridge University Hospitals National Health Service Foundation Trust, Hill''s Road, Cambridge, UK;7. Department of Gastrointestinal Surgery, San Raffaele Hospital, Milan, Italy;8. Department of Surgery, Katholieke Universiteit Leuven, Leuven, Belgium;9. General Surgery Department, Policlinico Gemelli University Hospital, Rome, Italy;10. Department of Academic Surgery, Royal Marsden NHS Foundation Trust, London, UK;11. Department of Surgical Oncology, Medical University of Lublin, Lublin, Poland;12. Unit of General Surgery and Surgical Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy;13. Department of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital of Leipzig, Leipzig, Germany;14. Department of Surgery, Jagiellonian University Medical College, Krakow, Poland;15. Department of Radiation Oncology, University Hospitals Leuven, Belgium;p. Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland;q. Department of Medical Oncology, Aarhus University, Aarhus, Denmark;r. Cancer Institute, University College London, London, UK;s. Department of Medical Oncology, Biomedical Research Institute, INCLIVA, University of Valencia, Spain;t. Department of Digestive Oncology, University Hospitals Leuven, Leuven, Belgium;u. Medical Department, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany;v. Department of Oncology, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland;w. Department of Medical Oncology, University Medical Centers Amsterdam, University of Amsterdam, Amsterdam, the Netherlands |
| Abstract: | BackgroundA uniform definition and treatment for oligometastatic esophagogastric cancer is currently lacking. However, a comprehensive definition of oligometastatic esophagogastric cancer is necessary to initiate studies on local treatment strategies (e.g. metastasectomy or stereotactic radiotherapy) and new systemic therapy agents in this group of patients. For this purpose, the OligoMetastatic Esophagogastric Cancer (OMEC) project was established. The OMEC-project aims to develop a multidisciplinary European consensus statement on the definition, diagnosis, and treatment for oligometastatic esophagogastric cancer and provide a framework for prospective studies to improve outcomes of these patients.MethodsThe OMEC-project consists of five studies, including 1) a systematic review on definitions and outcomes of oligometastatic esophagogastric cancer; 2) real-life clinical scenario discussions in multidisciplinary expert teams to determine the variation in the definition and treatment strategies; 3) Delphi consensus process through a starting meeting, two Delphi questionnaire rounds, and a consensus meeting; 4) publication of a multidisciplinary European consensus statement; and 5) a prospective clinical trial in patients with oligometastatic esophagogastric cancer.DiscussionThe OMEC project aims to establish a multidisciplinary European consensus statement for oligometastatic esophagogastric cancer and aims to initiate a prospective clinical trial to improve outcomes for these patients. Recommendations from OMEC can be used to update the relevant guidelines on treatment for patients with (oligometastatic) esophagogastric cancer. |
| Keywords: | Esophageal cancer Gastric cancer Oligometastasis Metastasectomy Radiotherapy OMD"} {"#name":"keyword" "$":{"id":"pc_aNmQRhnVfL"} "$$":[{"#name":"text" "_":"Oligometastatic disease SBRT"} {"#name":"keyword" "$":{"id":"pc_u03Gr5nhKw"} "$$":[{"#name":"text" "_":"Stereotactic body radiotherapy OS"} {"#name":"keyword" "$":{"id":"pc_pfJCScTl0z"} "$$":[{"#name":"text" "_":"Overall survival PFS"} {"#name":"keyword" "$":{"id":"pc_ykZ04p7jyv"} "$$":[{"#name":"text" "_":"Progression-free survival RCT"} {"#name":"keyword" "$":{"id":"pc_abnm4u7SYA"} "$$":[{"#name":"text" "_":"Randomized controlled trial NSCLC"} {"#name":"keyword" "$":{"id":"pc_IihzVUtMuL"} "$$":[{"#name":"text" "_":"Non-small-cell lung cancer FLOT"} {"#name":"keyword" "$":{"id":"pc_nj0Huc3EwA"} "$$":[{"#name":"text" "_":"Fluorouracil leucovorin oxaliplatin and docetaxel CapOx"} {"#name":"keyword" "$":{"id":"pc_NP1QR20gZm"} "$$":[{"#name":"text" "_":"Oxaliplatin and capecitabine HIPEC"} {"#name":"keyword" "$":{"id":"pc_vhlhTiTMgd"} "$$":[{"#name":"text" "_":"hyperthermic intraperitoneal chemotherapy HR"} {"#name":"keyword" "$":{"id":"pc_rLzlmEVPgj"} "$$":[{"#name":"text" "_":"Hazard ratio PET"} {"#name":"keyword" "$":{"id":"pc_xIo7IjHiN5"} "$$":[{"#name":"text" "_":"Positron emission tomography CT"} {"#name":"keyword" "$":{"id":"pc_CPNpKNBynA"} "$$":[{"#name":"text" "_":"Computed tomography MRi"} {"#name":"keyword" "$":{"id":"pc_83p7luniQu"} "$$":[{"#name":"text" "_":"Magnetic resonance imaging |
| 本文献已被 ScienceDirect 等数据库收录！ | |